Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Relief Therapeutics Holdings AG (QB) | RLFFD | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.2038 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 4.36 - 8.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 4.2038 | USD |
Relief Therapeutics Holdings AG (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
US$ 46.32M | 11.02M | 7.91M | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Relief Therapeutics (QB) News
Date | Time | Source | News Article |
---|---|---|---|
4/30/2024 | 15:31 | Edgar (US Regulatory) | Form 20-F - Annual and transition report of foreign private.. |
4/03/2024 | 15:31 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
3/27/2024 | 15:15 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
12/05/2023 | 15:30 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
11/22/2023 | 15:31 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
10/10/2023 | 16:00 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
9/15/2023 | 16:02 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
8/31/2023 | 16:24 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RLFFD Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 7.54 | 8.40 | 4.36 | 6.53 | 9,466 | -3.34 | -44.25% |
3 Years | 8.50 | 8.50 | 4.36 | 6.58 | 9,209 | -4.30 | -50.54% |
5 Years | 8.50 | 8.50 | 4.36 | 6.58 | 9,209 | -4.30 | -50.54% |
Relief Therapeutics (QB) Description
Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases, and connective tissue disorders. The parent company of the group, RELIEF THERAPEUTICS Holding SA, is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFFD and RLFTD. |